Solid Tumor
Conditions
Brief summary
This is a single-institution, single arm, open label, window of opportunity clinical trial that will act as a Master Protocol with a primary objective to assess pharmacodynamic effects of the novel study drugs in subjects with resectable solid tumor malignancies. Each Sub-protocol conducted under the Master Protocol will evaluate different novel therapeutic agent(s). Estimated enrollment is 15 subjects per Sub-Protocol.
Detailed description
Patients will have a short-course (4-weeks) administration of a given compound in the timeframe between the diagnostic biopsy and the surgical resection. A pre-treatment tumor biopsy will be obtained, and blood samples will be collected before, during, and at the end of treatment.
Interventions
DRUGEpacadostat
Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
Sponsors
Incyte Corporation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Must have biopsy-proven solid tumor that is eligible for elective surgical resection, disease does not require immediate therapy, and there is NO approved/ standard therapy available that is shown to prolong overall survival. 2. ECOG performance status of 0 or 1. 3. Must have a tumor lesion that is amenable to biopsy, and willing to undergo biopsy. 4. Willing to provide tissue and blood samples for research.
Exclusion criteria
1. The following solid tumors are NOT eligible: Primary brain tumor, Ocular melanoma, Head and neck cancer, Breast cancer, Prostate cancer, Testicular cancer, and Stage III rectal cancer. 2. Any active malignancy within 3 years prior, except: Adequately treated basal cell or squamous cell skin cancer, or early stage cancers (carcinoma in situ or stage 1) treated with curative intent. 3. Any uncontrolled intercurrent illness, including but not limited to: Symptomatic congestive heart failure, Unstable angina pectoris or coronary angioplasty or stenting within 6 months prior to enrollment, Cardiac arrhythmia, Psychiatric illness or social situations that would limit compliance with study requirements, or Ongoing or active infection. 4. Any known sensitivity to or history of allergic reaction to compounds of similar chemical or biological composition of study drug(s). 5. Unwilling or unable to follow the study schedule. Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamic effects as measured by changes in biomarkers in pre- and post-dose tumor and blood specimens | Approximately 1 year | To establish baseline levels and measure pharmacodynamic biomarker changes in tumor and/or blood samples after treatment with the study drug. Sub- Protocol A will focus on changes in CD8+ T cells, CD4+Foxp3+ cells, NK cells, DCs and immune checkpoints. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability as measured by incidence of AEs (Adverse Events) | Approximately 1 year | To assess the safety and tolerability of the study drug in the pre-surgical setting graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. |
| Pathological Response Rate as measured by correlation of biomarkers in tumor and/or blood specimens | Approximately 1 year | To evaluate pathological response rate of solid tumor malignancies in subjects receiving neo-adjuvant treatment with the study drug and to assess a possible correlation with biomarkers either in the tumor specimens either in the bloods samples and the pathological response. |
| Overall Survival | Approximately 2 years | To determine the overall survival (OS) status of subject treated which the study drug at 6 months, 1 year and 2 year |
Countries
United States
Outcome results
None listed